peptidylprolyl isomerase A pseudogene 26Genealiases: []
Q-omics provides the consensus-scored PPIAP26 profile across patient tissues and cancer cell-line models. PPIAP26 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, PPIAP26 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, PPIAP26 RNA expression shows 7,947 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight STAD, HNSC, and ESCA as cancer lineages where PPIAP26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAP26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAP26 survival associations across molecular data types. PPIAP26 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAP26 RNA expression–survival associations across cancer types. High PPIAP26 expression shows unfavorable associations in STAD, KICH, ACC and COAD, but favorable associations in SKCM and DLBC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify STAD as the clearest survival context for PPIAP26 RNA expression.
This table summarizes PPIAP26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAP26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAP26 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, LUSC, BRCA and READ. The HNSC box plot shows higher PPIAP26 RNA expression in tumor versus normal tissue (log2 FC = +2.568, t-test p < 0.001).
This table shows molecular features associated with PPIAP26 in patient tissues and cancer cell lines. In patient samples, PPIAP26 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
